Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy

Journal of the Neurological Sciences

Volumn 218, Issue 1-2, 2004, Pages 39-45

  Lorenzl, Stefan ^a   Albers, David S ^a   Chirichigno, Jason W ^a   Augood, Sarah J ^b   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Matrix metalloproteinases; Substantia nigra; Supranuclear palsy

Indexed keywords

BRAIN PROTEIN; GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN LEVEL; BRAIN TISSUE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION;

EID: 0842283363     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2003.10.015     Document Type: Article

References (34)

1. Steele J., Richardson J.C., Olszeewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol. 10:1964;333-359.
2. Hauw J.J., Daniel S.E., Dickson D., Horoupian D.S., Jellinger K., Lantos P.L.et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson- Olszewski syndrome (progressive supranuclear palsy). Neurology. 44:1994;2015-2019.
3. Litvan I., Hauw J., Bartko J., Lantos P.L., Daniel S.E., Horoupian D.S. et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J. Neuropathol. Exp. Neurol. 55:1996;97-105.
4. Albers D.S., Augood S.J. New insights into progressive supranuclear palsy. Trends Neurosci. 24:2001;347-353.
5. Stetler-Stevenson W.G. Dynamics of matrix turnover during pathological remodelling of the extracellular matrix. Am. J. Pathol. 148:1996;1345-1350.
6. Woessner J.F. The family of matrix metalloproteinases. Ann. N.Y. Acad. Sci. 732:1994;11-21.
7. Gottschall P.E., Deb S. Regulation of matrix metalloproteinase expression in astrocytes, microglia and neurons. Neuroimmunomodulation. 3:1996;69-75.
8. Asahina M., Yoshiyama Y., Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin. Neuropathol. 20:2001;60-63.
9. Miyazaki K., Hasegawa M., Funahashi K., Umeda M. A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature. 362:1993;839-841.
10. Backstrom J.R., Miller C.A., Tökés Z.A. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J. Neurochem. 58:1992;983-992.
11. Lim G.P., Backstrom J.R., Cullen M.J., Miller C.A., Atkinson R.D., Tokes Z.A. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J. Neurochem. 67:1996;251-259.
12. Beuche W., Yushchenko M., Mader M., Maliszewska M., Felgenhauer K., Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport. 11:2000;3419-3422.
13. Lorenzl S., Albers D.S., Narr S., Chirichigno J., Beal M.F. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp. Neurol. 178:2002;13-20.
14. Hayakawa T., Yamashita K., Ohuchi E., Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci. 107:1994;2373-2379.
15. Nemeth J.A., Rafe A., Steiner M., Goolsby C.L. TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp. Cell Res. 224:1996;110-115.
16. Sylvestre M.N., Balcerzak D., Feidt C., Baracos V.E., Brun Bellut J. Elevated rate of collagen solubilization and postmortem degradation in muscles of lambs with high growth rates: possible relationship with activity of matrix metalloproteinases. J. Anim. Sci. 80:2002;1871-1878.
17. Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J.et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8:1999;711-715.
18. Albers D.S., Augood S.J., Park L.C., Browne S.E., Martin D.M., Adamson J.et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J. Neurochem. 74:2000;878-881.
19. Zhang J.W., Gottschall P.E. Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. J. Neurosci. Methods. 76:1997;15-20.
20. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 34:1994;217-228.
21. Dunah A.W., Yasuda R.P., Wang Y.H., Luo J., Davila-Garcia M., Gbadegesin M.et al. Regional and ontogenic expression of the NMDA receptor subunit NR2D protein in rat brain using a subunit-specific antibody. J. Neurochem. 67:1996;2335-2345.
22. Augood S.J., Hollingsworth Z.R., Standaert D.G., Emson P.C., Penney J.B. Jr. Localization of dopaminergic markers in the human subthalamic nucleus. J. Comp. Neurol. 421:2000;247-255.
23. Nakamura H., Ueno H., Yamashita K., Shimada T., Yamamoto E., Noguchi M. et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res. 59:1999;467-473.
24. Yoshiyama Y., Ashina M., Hattori T. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol. 99:2000;91-95.
25. Leake A., Morris C.M., Whateley J. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neurosci. Lett. 291:2000;201-203.
26. Wang X., Mori T., Jung J.C., Fini M.E., Lo E.H. Secretion of matrix metallo-proteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. J. Neurotrauma. 19:2002;615-625.
27. Morita-Fujimura Y., Fujimura M., Gasche Y., Copin J., Chan P.H. Overexpression of copper and zinc superoxide dismutase in transgenic mice prevents the induction and activation of matrix metalloproteinases after cold injury induced brain trauma. J. Cereb. Blood Flow Metab. 20:1999;130-138.
28. Cantuti-Castelvetri I., Keller-McGandy C.E., Albers D.S., Beal M.F., Vonsattel J.P., Standaert D.G.et al. Expression and activity of antioxidants in the brain in progressive supranuclear palsy. Brain Res. 930:2002;170-181.
29. Vos C.M.P., Sjulson L., Nath A., McArthur J.C., Pardo C.A., Rothstein J.et al. Cytotoxicity by matrix metalloproteinase-1 in organotypic spinal cord and dissociated neuronal cultures. Exp. Neurol. 163:2000;324-330.
30. Rosenberg G.A., Sullivan N., Esiri M.M. White matter damage is associated with matrix metaloproteinases in vascular dementia. Stroke. 32:2001;1162-1168.
31. Clark A.W., Krekoski C.A., Bou S.S., Chapman K.R., Edwards D.R. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci. Lett. 238:1997;53-56.
32. Peress N., Perillo E., Zucker S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 54:1995;16-22.
33. Valente P., Fassina G., Melchiori A., Masiello L., Cilli M., Vacca A.et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer. 75:1998;246-253.
34. Costa S., Planchenault T., Charriere-Bertrand C., Mouchel Y., Fages C., Juliano S.et al. Astroglial permissivity for neuritic outgrowth in neuron-astrocyte cocultures depends on regulation of laminin bioavailability. Glia. 37:2002;105-113.